Product Name:
G6PD-pY503+pY507
Product Number:
ab-pn701
Target Full Name: Glucose-6-phosphate 1-dehydrogenase
Target Alias: G6PD; G6PD1; Glucose-6-phosphate 1-dehydrogenase; glucose-6-phosphate dehydrogenase
Product Type Specific: G6PD phosphosite-specific antibody
Antibody Code: PN701
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y503+Y507
Protein UniProt: P11413
Protein SigNET: G6PD
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human G6PD
Antibody Immunogen Sequence: GFQ(pY)EGT(pY)KWV(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues G500 to V510. The effects of Y503 and Y507 phosphorylation are unclear. These are two of the major in vivo phosphorylation sites in G6PD (≥961 and >771 reports, respectively, by mass spectrometry). These phosphosites are highly conserved in vertebrates and also found in the nematode worm. G6PD is known to be phosphorylated in vitro at Y507 by Src.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.6 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus macaque | Dog | Rat | Mouse | Platypus | Frog| Zebra fish | Tiger blowfish.
Related Product 1: G6PD Y401 phosphorylation antibody (Cat. No.: AB-PN515)
Scientific Background: G6PD catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a major route for the dissimilation of carbohydrates in addition to glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. The biochemical reaction catalyzed is: D-glucose 6-phosphate + NADP+ = 6-phospho-D-glucono-1,5-lactone + NADPH. G6PD activity is essential for maintaining redox homeostasis, supplying NADPH for biosynthetic processes (lipid/nucleotide synthesis), and protecting cells—especially red blood cells (RBCs)—from oxidative damage. G6PD is active as a homodimer or homotetramer (side-by-side dimer of dimers), whereas the monomeric form is inactive. It is primarily cytosolic, with some association with the endoplasmic reticulum. Acetylation of Lys403 by KAT9/ELP3 inactivates G6PD, while SIRT2-dependent deacetylation activates it under oxidative stress. Fyn kinase (Src family) phosphorylates G6PD in RBCs to activate it. Src-family kinases generally increase G6PD activity to promote tumor metabolism. O-GlcNAcylation increases under hypoxia, increasing NADP+ binding affinity and increasing enzyme activity. High levels of NADPH act as a competitive inhibitor, while p53 can directly bind to and inhibit the formation of the active G6PD dimer. CG6PD deficiency is the most common enzyme deficiency worldwide and affects ~400–500 million people.The high prevalence of G6PD deficiency in tropical regions is likely due to selection pressure from malaria, as the deficiency offers partial protection against severe cases of Plasmodium falciparum. G6PD is frequently upregulated in various cancers (e.g., breast, lung, leukemia) to meet high NADPH demands for proliferation and to resist chemotherapy-induced oxidative stressThis description may include information annotated by UniProt and/or Google AI.